Search Results
Aug 27, 2026, 19:19 ET Au Royaume-Uni, le NICE publie des recommandations préconisant le financement systématique par le NHS du système de perfusion hypothermique oxygénée VitaSmart™ de Bridge to Life
large adoption internationale en Europe et d'une croissance commerciale rapide aux États-Unis suite à l'autorisation de novo délivrée par la Food and Drug Administration (FDA), Bridge to Life reste déterminé à faire progresser la science de la conservation fondée sur des données probantes, afin d'élargir
More news about: Bridge to Life, Ltd.
Aug 27, 2026, 19:00 ET /C O R R E C T I O N -- Bridge to Life, Ltd./
better outcomes for our patients."With broad international adoption across Europe and rapid commercial growth in the U.S. following its Food and Drug Administration (FDA) De Novo clearance, Bridge to Life remains committed to advancing evidence-based preservation science that expands the donor pool
More news about: Bridge to Life, Ltd.
Aug 27, 2026, 18:58 ET Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion
Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.By implementing the ExellenS™ framework across its manufacturing network with standardized designs,
More news about: Samsung Biologics
Aug 27, 2026, 17:33 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CAPR
information about joining the class action]In late 2024, Capricor submitted its Biologics License Application ("BLA") to the U.S. Food and Drug Administration for Deramiocel as a cell therapy for the treatment of Duchenne muscular dystrophy. In July 2025, the FDA issued a Complete Response Letter
More news about: Pomerantz LLP
Aug 27, 2026, 17:30 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Wise Group plc of Class Action Lawsuit and Upcoming Deadlines - WSE
nearing completion, concerns potential money laundering offences, with alleged links to fraud, corruption and drug trafficking" and that "[p]rosecutors are investigating whether Wise Europe's services were used by international criminal organisations,
More news about: Pomerantz LLP
Aug 27, 2026, 17:18 ET UK NICE Issues Guidance Recommending Routine NHS Funding for Bridge to Life's VitaSmart™ Hypothermic Oxygenated Perfusion System
outcomes for our patients." With broad international adoption across Europe and rapid commercial growth in the U.S. following its Food and Drug Administration (FDA) De Novo clearance, Bridge to Life remains committed to advancing evidence-based preservation science that expands the donor pool
More news about: Bridge to Life, Ltd.
Aug 27, 2026, 16:40 ET SpyGlass Pharma Celebrates Grand Opening of New Irvine Headquarters, Positioning Itself for First Product Launch and Custom R&D Space
patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The Company's mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence
More news about: City of Irvine and SpyGlass Pharma
Aug 27, 2026, 16:09 ET Kazia Therapeutics Limited Announces Proposed Public Offering
nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma in August 2020. Paxalisib was also
More news about: Kazia Therapeutics Limited
Aug 27, 2026, 16:04 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors - AARD
2, 2026.Then, on May 14, 2026, Aardvark issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has placed a full clinical hold on its investigational new drug application (IND) for ARD-101 related to the Company's previously announced voluntary pause."The press release
More news about: Pomerantz LLP
Aug 27, 2026, 16:04 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Fractyl Health, Inc. and Certain Officers - GUTS
evaluating Revita's efficacy in maintaining weight loss following the discontinuation of GLP-1 receptor agonist drug therapy. The REMAIN-1 study is designed to include three distinct patient cohorts: (i) the REVEAL-1 Cohort; (ii) the REMAIN-1 Midpoint Cohort; and
More news about: Pomerantz LLP
Aug 27, 2026, 16:01 ET Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma in August 2020. Paxalisib was also
More news about: Kazia Therapeutics Limited
Aug 27, 2026, 15:17 ET Evonik expands lipid-based drug delivery capabilities with new GMP manufacturing facility in Vancouver
ESSEN, Germany, Aug. 27, 2026 /PRNewswire/ -- Evonik is investing in a new GMP drug product manufacturing facility for lipid-based drug delivery in Vancouver, Canada. The facility will increase Evonik's development and manufacturing capacity, helping
More news about: Evonik Industries AG
Aug 27, 2026, 11:03 ET Kowa Pharmaceuticals America Announces FDA Acceptance of New Drug Application for K-911, an Investigational IOP-Lowering Eye Drop for Patients with Open-Angle Glaucoma or Ocular Hypertension
Aug. 27, 2026 /PRNewswire/ -- Kowa Pharmaceuticals America, Inc. (KPA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for K-911 (bimatoprost grenod, also known as NCX 470), an investigational topical ophthalmic monotherapy
More news about: Kowa Pharmaceuticals America, Inc.
Aug 27, 2026, 10:15 ET CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
ESMO 2026 in October. The Company also expects to reach consensus with global regulatory authorities including the U.S. Food and Drug Administration (FDA) and the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA), on the global Phase III registrational trial protocol
More news about: CStone Pharmaceuticals
Aug 27, 2026, 10:09 ET Harbour BioMed Appoints Mr. Youchen Chen and Dr. Ian Y. Liu as Executive Directors
said: "It is a true privilege to continue serving Harbour BioMed as an Executive Director. The Company has always stood at the forefront of innovative drug discovery and development. In the areas of global legal compliance and intellectual property strategy, I will continue to leverage my professional expertise
More news about: Harbour BioMed
Aug 27, 2026, 10:04 ET Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy
across the antibody drug discovery and development process to enhance R&D efficiency. The Company has established a technology platform matrix spanning a broad range of therapeutic modalities, including bispecific and multi-specific antibodies, T-cell engagers (TCEs), antibody-drug conjugates (ADCs)
More news about: Harbour BioMed
Aug 27, 2026, 10:00 ET New Drug Application for "K-911" Targeting Patients with Glaucoma and Ocular Hypertension Accepted for Filing in the U.S., Food and Drug Administration
today announced that the New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) on June 30, 2026 has been accepted for filing. The FDA will conduct its review of the NDA with a target action date of April 30, 2027, under the Prescription Drug User Fee Act (PDUFA).
More news about: Kowa Company Ltd.
Aug 27, 2026, 10:00 ET Ceruvia Strengthens Intellectual Property Position for BOL-148 with Three U.S. Patent Allowances and Unitary Patent Grant in Europe
tightly control LSD and other process-related impurities. Together, the allowances and grant add important layers of protection around both the drug product and its manufacture and form part of Ceruvia's broader intellectual property portfolio covering BOL-148. For example, Ceruvia is pursuing patent
More news about: Ceruvia Lifesciences
Aug 27, 2026, 09:19 ET LUXE Bidet Named Winner at NACDS Total Store Expo for Second Consecutive Year
NACDS, the National Association of Chain Drug Stores, hosts TSE annually as its flagship event for retail buyers, pharmacy leaders, and suppliers. The Product Showcase specifically highlights
More news about: LUXE Bidet
Aug 27, 2026, 08:55 ET HUM Nutrition Launches Stack & Sculpt™, a Peptide-Powered Creatine for Toning
nuritas.com.*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.‡Based on published clinical research on PeptiStrong®
More news about: HUM Nutrition
Aug 27, 2026, 08:44 ET Iylon Precision Oncology, LLC Appoints Dr. Mary Lopresti as Chief Medical Officer
discussions and individualized care planning."Mary understands that precision oncology is not simply about identifying a mutation or recommending a drug," said Sendurai A. Mani, Ph.D., Co-founder and Chief Scientific Officer of Iylon. "It requires integrating the patient's clinical history, tumor
More news about: Iylon Precision Oncology
Aug 27, 2026, 08:30 ET FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the release of the third batch of its CYWC628 drug product and its shipment to Australia in support of the ongoing Phase 1/2 clinical trial in patients with diabetic foot ulcers (DFUs). The batch was
More news about: FibroBiologics, Inc.
Aug 27, 2026, 08:30 ET Assessing the Use of Non-Human Primates in Translational Research Today, Upcoming Webinar Hosted by Xtalks
This opening session examines how NHP models function as a translational bridge from bench to bedside, why they continue to occupy a distinct place in drug development, and how their use is continually reassessed as alternative methods to NHP models advance.The session traces the evolution of NHP
More news about: Xtalks
Aug 27, 2026, 08:30 ET Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer
developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving,
More news about: Caris Life Sciences
Aug 27, 2026, 08:20 ET Neopharma Technologies Achieves ISO/IEC 42001:2023 AI Management System Certification for NEOVAULT® Global Diagnostics Platform
laboratories and enterprise systems within a secure and traceable digital environment.While initial deployments are focused on workplace health and drug and alcohol testing, the platform architecture has been designed to support expansion into broader human health diagnostic applications over time.About
More news about: Neopharma Technologies Ltd